Follitropin-α (Gonal-F) versus follitropin-β (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?

Raoul Orvieto, Ravit Nahum, Jacob Rabinson, Jacob Ashkenazi, Eyal Y. Anteby, Simion Meltcer

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

In an attempt to examine and compare the effect of the two commercially available recombinant FSH on ovarian stimulation characteristics and IVF cycle outcome, we studied 264 IVF cycles in patients with a favorable prognosis a priori, 198 in patients using follitropin-α, and 68 in patients using follitropin-β. Although both groups achieved a comparable number of retrieved oocytes, the use of follitropin-β was associated with a tendency toward a lower clinical pregnancy rate (PR), and with significantly higher E2 levels despite the use of significantly lower total gonadotropin dose.

Original languageEnglish
Pages (from-to)1522-1525
Number of pages4
JournalFertility and Sterility
Volume91
Issue number4 SUPPL.
DOIs
StatePublished - 1 Apr 2009

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Follitropin-α (Gonal-F) versus follitropin-β (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?'. Together they form a unique fingerprint.

Cite this